一种基于双价外膜囊泡的鼻内疫苗用于预防牙周致病菌感染
本研究评估了利用牙龈卟啉单胞菌(Pg)和伴放线聚集杆菌(Aa)外膜囊泡(OMV)制备鼻内疫苗预防牙周病的策略。比较显示Aa OMV表面更光滑、脂质A活性更强,体外免疫活性显著强于Pg OMV。小鼠鼻内免疫后,Aa OMV单独可诱导血液和唾液中强效体液免疫;作为黏膜佐剂可增强Pg特异性IgG和IgA应答,效果优于Poly(I:C)。随机盲法实验中,免疫小鼠口腔攻击后两种菌数量显著低于模拟免疫组,脑内注射未观察到严重不良反应。双价OMV鼻内疫苗可能有效预防牙周致病菌定植及相关全身性疾病。
要点
- Aa OMV的脂质A活性和体外免疫活性显著强于Pg OMV。
- Aa OMV作为黏膜佐剂可增强Pg特异性血清IgG和唾液IgA应答。
- 双价OMV鼻内免疫小鼠口腔攻击后Pg和Aa数量显著低于模拟免疫组。
核心结论
- 双价OMV鼻内疫苗可能有效预防牙周致病菌在口腔的定植及牙周病相关全身性疾病。
研究设计与样本
- 研究比较了Pg ATCC 33277和Aa Y4的OMV形态、组成和免疫活性,并在小鼠中进行鼻内免疫、口腔攻击和脑内注射实验。
- 口腔攻击实验采用随机盲法设计,比较免疫组与模拟免疫组。
主要发现
- Aa OMV表面比Pg OMV更光滑,脂质A活性更强。
- Aa OMV在巨噬细胞样细胞中诱导的体外免疫活性显著强于Pg OMV。
- 小鼠鼻内免疫Aa OMV单独可诱导血液和唾液中强效体液免疫应答。
- Aa OMV作为黏膜佐剂可增强Pg特异性血清IgG和唾液IgA应答,且两者均凝集Pg和Aa细胞。
- 在增强Pg特异性IgG(尤其IgG2a)和IgA产生方面,Aa OMV作为黏膜佐剂比Poly(I:C)更有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Periodontal disease has become a serious public health problem, not only causing tooth loss, but also inducing chronic disorders of extra-oral organs. The present study assessed an intranasal vaccine strategy to prevent periodontal disease using outer membrane vesicles (OMVs) of two major periodontopathic bacteria, Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa). We compared the morphology, composition, and immune activity between OMVs of Pg strain ATCC 33277 and Aa strain Y4. Aa OMVs had a smoother surface and stronger lipid A activity compared to Pg OMVs. The in vitro immune activity elicited by Aa OMVs in macrophage-like cells was remarkably stronger than that of Pg OMVs. Intranasal immunization of mice with Aa OMVs alone resulted in robust, humoral immune responses in blood and saliva. Despites the intrinsically low mucosal immunogenicity of Pg OMVs alone, using Aa OMVs as a mucosal adjuvant strongly enhanced Pg-specific immune responses, resulting in both serum IgG and salivary IgA, both of which aggregated Pg and Aa cells. Furthermore, Aa OMVs were found to be a more potent mucosal adjuvant than Poly(I:C) in the context of enhancing the production of Pg-specific IgG (especially IgG2a) and IgA. In addition, in a randomized, blinded study, mice oral challenged with Pg and Aa after intranasal immunization with Pg OMVs and Aa OMVs had significantly decreased numbers of both microorganisms compared to mock-immunized mice. Furthermore, in an intracerebral injection mouse model, there were no serious adverse effects on the brain even after administrating a dose of OMVs as same as that used for intranasal administration. Taken together, the bivalent OMV intranasal vaccine may be effective in preventing colonization of periodontopathic bacteria in the oral cavity and related systemic disorders associated with periodontal diseases.
引用
- Nakao R, Hirayama S, Yamaguchi T, et al. A bivalent outer membrane vesicle-based intranasal vaccine to prevent infection of periodontopathic bacteria. Vaccine. 2023. PMID: 37302966. doi:10.1016/j.vaccine.2023.05.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。